文献速递炎症性肠病

基线清除率与早期谷浓度识别英夫利西单抗诱导治疗中早期治疗药物监测候选者

Baseline Clearance and Early Troughs Identify Candidates for Early Therapeutic Drug Monitoring During Infliximab Induction in Inflammatory Bowel Disease.
PubMed 文献 · Aliment Pharmacol Ther · 2026-10-25

该多中心4期研究分析75例炎症性肠病患者英夫利西单抗诱导治疗药代动力学,评估基线清除率和早期暴露指标能否识别早期治疗药物监测候选者。溃疡性结肠炎中基线清除率和第6周谷浓度对联合缓解有强判别力,基线清除率>0.28 L/day和第6周谷浓度≤21.6 mg/L识别高风险的缓解率极低亚组,克罗恩病未发现稳健预测因子。

要点

  • 溃疡性结肠炎基线清除率和第6周谷浓度可强判别联合缓解。
  • 基线清除率>0.28 L/day或第6周谷浓度≤21.6 mg/L者缓解率极低。
  • 克罗恩病未发现稳健的暴露-反应预测因子。

核心结论

  • 以基线清除率和早期谷浓度为中心的风险分层模型指导方法可能指导溃疡性结肠炎英夫利西单抗个体化诱导治疗。
  • 克罗恩病中未发现稳健预测因子。
  • 需外部验证。

研究设计与样本

  • 多中心4期研究,成人克罗恩病和溃疡性结肠炎患者接受标准英夫利西单抗治疗(5 mg/kg,第0、2、6、14、22、30周),预设峰值、中间和谷浓度采样。
  • 采用群体药代动力学模型表征处置和协变量,逻辑回归评估暴露-反应关系。

主要发现

  • 较低血清白蛋白、较高体重和抗英夫利西单抗抗体增加清除率。
  • 溃疡性结肠炎中基线清除率和模型预测第6周谷浓度对联合缓解的ROC曲线下面积分别为0.88(95%CI 0.75-1.00)和0.86(95%CI 0.69-1.00)。
  • 基线清除率>0.28 L/day和第6周谷浓度≤21.6 mg/L识别高风险亚组,缓解数分别为0/18和1/20(p<0.05)。

关键数值与推荐

  • 主要结局为第30周联合缓解:克罗恩病Harvey-Bradshaw指数≤4;溃疡性结肠炎部分Mayo评分≤2;且粪钙卫蛋白<100 μg/g和C反应蛋白≤5 mg/L。
  • 溃疡性结肠炎基线清除率>0.28 L/day和第6周谷浓度≤21.6 mg/L为高风险亚组阈值。

临床怎么用

  • 溃疡性结肠炎患者可考虑基于基线清除率和第6周谷浓度进行风险分层,识别早期治疗药物监测候选者。
  • 克罗恩病患者暂缺乏稳健预测因子指导早期治疗药物监测。

局限性

  • 克罗恩病中未发现稳健预测因子。
  • 需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The value of therapeutic drug monitoring during infliximab induction remains uncertain. We evaluated whether baseline infliximab clearance and early exposure metrics identify candidates for potential early proactive therapeutic drug monitoring during induction in inflammatory bowel disease. METHODS: We analysed a multicenter Phase 4 study in which adults with Crohn's disease and ulcerative colitis initiated standard infliximab therapy (5 mg/kg at Weeks 0, 2, 6, 14, 22 and 30) with predefined peak, intermediate and trough sampling. A population pharmacokinetic model characterized disposition and covariates. Logistic regression assessed exposure-response relationships. The primary outcome was week-30 combined remission (Crohn's disease: Harvey-Bradshaw Index ≤ 4; ulcerative colitis: Partial Mayo score ≤ 2; with faecal calprotectin < 100 μg/g and C-reactive protein ≤ 5 mg/L). RESULTS: Seventy-five participants (33 female; median age 39 years, interquartile range 28-52) contributed pharmacokinetic data. Sixty-three were evaluable for exposure-response analyses. Twelve participants (19%) achieved combined remission (7/35 Crohn's disease; 5/28 ulcerative colitis). Lower serum albumin, higher body weight, and antibodies to infliximab increased clearance. In ulcerative colitis, baseline clearance and model-predicted week-6 trough concentration showed strong discrimination for combined remission (area under the receiver operating characteristic curve 0.88, 95% confidence interval 0.75-1.00; and 0.86, 0.69-1.00, respectively). Baseline clearance > 0.28 L/day and week-6 trough ≤ 21.6 mg/L identified high-risk subgroups with few remissions (0/18 and 1/20, respectively, p < 0.05). No robust predictors were identified in Crohn's disease. CONCLUSIONS: A pragmatic, risk-stratified, model-informed approach centered on baseline clearance and early troughs may guide personalized infliximab induction in ulcerative colitis. External validation is warranted. TRIAL REGISTRATION: EudraCT number: 2015-004618-10.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Mohamedi JA, Hoffert Y, Geukens N, et al. Baseline Clearance and Early Troughs Identify Candidates for Early Therapeutic Drug Monitoring During Infliximab Induction in Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2026. PMID: 42928429. doi:10.1111/apt.71062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。